One To Watch

Mestag Therapeutics

A private biotechnology company developing immunotherapies based on fibroblast-immune biology. Mestag Therapeutics focuses on first-in-class antibody therapies designed to modulate immune responses in cancer and inflammatory diseases.

Company Overview

Mestag Therapeutics is an immunology-focused biotechnology company developing therapies that target interactions between fibroblasts and immune cells. Its strategy centers on leveraging emerging insights into the role of stromal biology in disease to create new therapeutic approaches.

The company is focused on addressing a major limitation in current treatment paradigms: a large proportion of patients with cancer and inflammatory diseases do not respond adequately to existing therapies. Its approach aims to redirect immune activity by modulating fibroblast-driven signaling pathways that influence immune cell behavior.

Mestag operates as a discovery and early clinical-stage biotech, advancing a pipeline of antibody therapies while also generating new targets through its internal discovery platform.

Headquarters and Global Presence

headquartered in Cambridge, United Kingdom
research operations centered at Chesterford Research Park with collaborations across academic and industry partners globally

The company conducts research through partnerships with academic institutions, contract research organizations and pharmaceutical collaborators.

Founding and History

founded in 2020 as a spin-out based on academic research in fibroblast biology
backed by venture investors including Forbion, GV, Johnson & Johnson Innovation and Northpond Ventures

The company was established to translate advances in understanding stromal biology and immune regulation into therapeutic development. Its founding scientific work draws on research from institutions including the University of Oxford, Harvard Medical School and Cold Spring Harbor Laboratory.

Since launch, Mestag has expanded its platform and pipeline through collaborations with pharmaceutical companies and grant funding.

Therapy Areas and Focus

Mestag develops therapies across immunology-driven diseases.

Key areas of focus include:

oncology, particularly solid tumors
inflammatory and autoimmune diseases
diseases driven by immune dysfunction and stromal signaling

The company prioritizes indications where fibroblast-immune interactions play a central role in disease progression or treatment resistance.

Technology Platforms and Modalities

The company’s platform is based on fibroblast immunology and antibody engineering.

Key components include:

agonist and modulatory antibody therapies targeting fibroblast-immune pathways
RAFT (fibroblast-focused) target discovery platform
targeting of stromal biology and tertiary lymphoid structures
identification of inhibitor receptors regulating immune cell activity

This approach is designed to influence immune responses indirectly by modulating the tumor microenvironment or inflammatory tissue context.

Key Pipeline and Programs

Antibody-based immunotherapy programs

Modality: agonist and modulatory antibodies
Indication focus: cancer and inflammatory diseases
Status: preclinical and early development
Mechanism: modulation of fibroblast-immune signaling pathways to enhance or suppress immune activity

MST-0312

Modality: antibody-based immunotherapy
Indication focus: oncology
Status: advancing toward clinical development with support from Innovate UK funding

RAFT discovery platform programs

Modality: target discovery and validation platform
Application: identification of novel fibroblast-mediated immune targets
Status: ongoing discovery and partnered research

The pipeline is largely early-stage, with multiple programs emerging from internal discovery efforts.

Key Personnel

Susan Hill, Chief Executive Officer
Pascal Merchiers, Chief Development Officer
Robert de Jonge, Chief Business Officer

The leadership team includes experts in immunology, drug development and biotechnology partnerships.

Strategic Partnerships

Mestag operates with a collaboration-driven model.

Key partnerships include:

MSD (Merck & Co.), collaboration to identify novel inflammatory disease targets using the RAFT platform
Johnson & Johnson (Janssen), target discovery and licensing agreement in inflammatory disease
VIB, collaboration on nanobody development for oncology targets
Innovate UK, grant funding supporting oncology program development

These partnerships provide validation of the platform and support both discovery and translational development.

FAQ Section

The central strategic issue is whether targeting fibroblast-immune interactions can translate into clinically meaningful therapies. The company’s platform is based on emerging biology, and its success depends on demonstrating that modulation of stromal signaling can reliably improve outcomes in cancer and inflammatory diseases.

Fibroblasts play a key role in shaping the tissue environment and regulating immune responses. In cancer and inflammatory diseases, they can suppress or misdirect immune activity, contributing to disease progression and treatment resistance.

The company focuses on the stromal component of disease biology rather than targeting immune cells directly. By modulating fibroblast-driven signaling, its therapies aim to indirectly control immune responses in a more targeted way.

RAFT is the company’s internal discovery platform used to identify new therapeutic targets based on fibroblast-immune interactions. It supports both internal pipeline development and external collaborations.

Partnerships are central to the company’s model, providing funding, validation and downstream development capabilities. Collaborations with large pharmaceutical companies also expand the scope of target discovery.

Mestag is an early-stage biotechnology company with programs primarily in preclinical and early translational development.

Key issues include: